Once-weekly GZR18 significantly cuts HbA1c by up to 1.81% in Chinese T2DM patients
Background
Type 2 Diabetes Mellitus (T2DM) is a chronic metabolic disorder characterized by hyperglycemia, often leading to severe micro- and macrovascular complications. Current standard-of-care treatments, including existing glucagon-like peptide-1 receptor agonists (GLP-1 RAs), have significantly improved glycemic control and cardiovascular outcomes. However, there remains a need for novel, long-acting GLP-1 RAs with favorable safety profiles, particularly for specific populations like Chinese patients, to enhance treatment adherence and achieve sustained metabolic benefits. This study investigates GZR18, a new long-acting GLP-1 analog, to address this gap.
Study Design
This randomized, double-blind, placebo-controlled phase 1b/2a trial evaluated the safety and efficacy of once-weekly GZR18 in 72 Chinese adults with T2DM. The study was divided into two parts: Part A involved dose-titration of GZR18 from 0.5 mg to 4 mg over 26 weeks, while Part B titrated GZR18 from 1.5 mg to 13 mg over 23 weeks. Participants received either GZR18 or placebo once-weekly via subcutaneous injection. The primary endpoint was change in glycated hemoglobin (HbA1c), with secondary endpoints including body weight and other metabolic parameters. Adverse events were monitored for safety assessment.
Results
Once-weekly GZR18 demonstrated significant reductions in glycated hemoglobin (HbA1c) compared to placebo in both study parts. In Part A, GZR18 treatment resulted in an HbA1c reduction of -1.32%, while the placebo group showed an increase of 0.86%. In Part B, the higher dose-titration regimen of GZR18 led to an even greater HbA1c reduction of -1.81%, compared to a 0.12% increase in the placebo group.
Improvements in body weight and other metabolic parameters were also consistently observed across both GZR18 treatment arms. The compound was generally safe and well tolerated, with the most common adverse events being mild-to-moderate gastrointestinal issues. Crucially, no severe hypoglycemia episodes or treatment-related serious adverse events were reported, supporting its favorable safety profile. Overall, 62 of the 72 enrolled participants completed the trial.
Key Findings
- Once-weekly GZR18 reduced HbA1c by -1.32% in Part A (vs. +0.86% for placebo).
- Once-weekly GZR18 reduced HbA1c by -1.81% in Part B (vs. +0.12% for placebo).
- Improvements in body weight and other metabolic parameters were observed with GZR18.
- GZR18 was safe and well tolerated, with mostly mild-to-moderate gastrointestinal adverse events.
- No severe hypoglycemia or treatment-related serious adverse events occurred with GZR18.
Why It Matters
These findings position GZR18 as a promising new long-acting GLP-1 receptor agonist for the management of type 2 diabetes, particularly for Chinese patients. The observed significant HbA1c reductions, coupled with improvements in body weight and a favorable safety profile, suggest that GZR18 could offer an effective once-weekly treatment option. For individuals managing T2DM, this could mean better glycemic control with fewer injections and potentially improved adherence. The absence of severe hypoglycemia is a critical safety advantage. While this is an early-phase trial, the positive results warrant further investigation in larger, longer-term studies to confirm its efficacy and safety across broader populations and to establish optimal dosing strategies for clinical use.
gzr18
glp-1-agonist
type-2-diabetes
t2dm
phase-1b-2a
clinical-trial